The Alzheimer's Drug Discovery Foundation (ADDF) is a non-profit organization dedicated to accelerating the development of drugs to treat and prevent Alzheimer's disease. Founded in 1998 by the Charles and Ann Johnson Foundation, the ADDF focuses on funding innovative research aimed at understanding the disease’s mechanisms and discovering new therapeutic approaches. The foundation's goal is to advance drug development by supporting early-stage research and offering critical funding to academic and biotech companies.

The ADDF supports a variety of projects, including studies on disease-modifying treatments, as well as those targeting underlying causes of Alzheimer’s, such as inflammation, metabolic issues, and vascular dysfunction. By fostering partnerships with both scientific communities and industry leaders, the ADDF plays a pivotal role in advancing the pipeline of Alzheimer’s therapies.

Their approach is unique in its focus on collaboration and accelerating the transition of promising research from the lab to clinical trials. Through its grants and investments, the ADDF is committed to ensuring that groundbreaking Alzheimer’s therapies reach patients as quickly as possible, aiming for a future where Alzheimer's disease can be effectively treated or even prevented.